Lixisenatide

• Recruiting NCT NCT06671587

  iGlarLixi CGM Study in Chinese T2D Individuals After OADs

  Not yet reported Sanofi 678 participants Est. completion 2026-09-18 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Recruiting NCT NCT07307235

  Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

  Not yet reported Shanghai Zhongshan Hospital 1316 participants Est. completion 2027-12-30 24 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00299871

  Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

  Not yet reported Sanofi 542 participants Est. completion 2007-08 7 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00688701

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

  Not yet reported Sanofi 361 participants Est. completion 2009-12 12 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00707031

  GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

  Not yet reported Sanofi 639 participants Est. completion 2010-11 18 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00712673

  GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

  Not yet reported Sanofi 680 participants Est. completion 2011-03 16 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00713830

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

  Not yet reported Sanofi 859 participants Est. completion 2011-01 16 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00715624

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

  Not yet reported Sanofi 496 participants Est. completion 2011-02 15 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00763451

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

  Not yet reported Sanofi 484 participants Est. completion 2011-01 15 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00763815

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

  Not yet reported Sanofi 484 participants Est. completion 2011-06 150 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00866658

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

  Not yet reported Sanofi 311 participants Est. completion 2010-06 4 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00905255

  GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)

  Not yet reported Sanofi 69 participants Est. completion 2011-01 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00931372

  Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

  Not yet reported Sanofi 22 participants Est. completion 2009-08 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00975286

  24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

  Not yet reported Sanofi 446 participants Est. completion 2011-08 140 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00976937

  24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

  Not yet reported Sanofi 319 participants Est. completion 2011-03 92 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01146678

  Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

  Not yet reported Sanofi 22 participants Est. completion 2011-01 1 site Stand-alone
  Other conditions: Type 1 Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT01147250

  Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

  Not yet reported Sanofi 6068 participants Est. completion 2015-02 829 sites Stand-alone
  Other conditions: Acute Coronary Syndrome
  View official trial listing →
• Completed NCT NCT01169779

  Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

  Not yet reported Sanofi 391 participants Est. completion 2011-12 35 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01175473

  Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

  Not yet reported Sanofi 148 participants Est. completion 2010-11 7 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01476475

  Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

  Not yet reported Sanofi 323 participants Est. completion 2012-12 70 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01517412

  Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

  Not yet reported Sanofi 451 participants Est. completion 2013-05 82 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01572649

  Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

  Not yet reported Sanofi 24 participants Est. completion 2014-03 6 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01596504

  Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

  Not yet reported Sanofi 142 participants Est. completion 2013-07 8 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01632163

  Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

  Not yet reported Sanofi 447 participants Est. completion 2015-05 51 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01768559

  Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

  Not yet reported Sanofi 894 participants Est. completion 2014-12 199 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01798706

  Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

  Not yet reported Sanofi 350 participants Est. completion 2015-02 83 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01910194

  Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

  Not yet reported Profil Institut für Stoffwechselforschung GmbH 39 participants Est. completion 2014-10 2 sites
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT01940965

  Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

  Not yet reported Sanofi 294 participants Est. completion 2015-07 27 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01960179

  Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

  Not yet reported Sanofi 361 participants Est. completion 2015-03 30 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01973231

  Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

  Not yet reported Novo Nordisk A/S 404 participants Est. completion 2014-11 61 sites
  Type 2 diabetes Other conditions: Diabetes
  View official trial listing →
• Completed NCT NCT02020629

  Study on Lixisenatide and Counterregulation to Hypoglycemia

  Not yet reported Lund University 18 participants Est. completion 2015-08 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02049034

  Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

  Not yet reported University of Surrey 8 participants Est. completion 2016-01 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02058147

  Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

  Not yet reported Sanofi 1170 participants Est. completion 2015-06 273 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02058160

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

  Not yet reported Sanofi 736 participants Est. completion 2015-07 236 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02168491

  Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

  Not yet reported Medical University of Vienna 10 participants Est. completion 2015-08 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02200991

  Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

  Not yet reported Sanofi 136 participants Est. completion 2015-11 20 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT02231658

  Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

  Not yet reported Profil Institut für Stoffwechselforschung GmbH 109 participants Est. completion 2018-07-23 2 sites Stand-alone
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Terminated NCT NCT02244164

  Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

  Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 site
  Type 2 diabetes Other conditions: Incretinomimetics, Pancreas
  View official trial listing →
• Terminated NCT NCT02274740

  Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

  Not yet reported Sanofi 2 participants Est. completion 2015-08 Stand-alone
  Other conditions: Type II Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT02276196

  Effect of LIXIsenatide on the Renal System

  Not yet reported Amsterdam UMC, location VUmc 40 participants Est. completion 2016-04 1 site Stand-alone
  Chronic kidney disease Other conditions: Diabetes Mellitus, Glucagon-Like Peptide 1
  View official trial listing →
• Status unknown NCT NCT02308254

  Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

  Not yet reported, Not yet reported Royal Adelaide Hospital 30 participants Est. completion 2016-04 1 site
  Other conditions: Diabetes Mellitus, Gastroparesis
  View official trial listing →
• Status unknown NCT NCT02501850

  The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

  Not yet reported Hospital Universitari Vall d'Hebron Research Institute 40 participants Est. completion 2015-10 1 site Added to GLP-1
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02640118

  The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

  Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2016-07
  Other conditions: Diabetes After Total Pancreatectomy
  View official trial listing →
• Completed NCT NCT02713477

  Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

  Not yet reported Sanofi 20 participants Est. completion 2016-06 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02745470

  Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

  Not yet reported Seoul National University Hospital 30 participants Est. completion 2016-12 1 site Stand-alone
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT02749890

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

  Not yet reported Sanofi 321 participants Est. completion 2018-05 61 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02752412

  Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

  Not yet reported Sanofi 513 participants Est. completion 2018-10-04 122 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02752828

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

  Not yet reported Sanofi 521 participants Est. completion 2018-03-12 113 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT02767596

  Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

  Not yet reported Laniado Hospital 2 participants Est. completion 2017-02-21 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02787551

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

  Not yet reported Sanofi 514 participants Est. completion 2018-11-17 124 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02803918

  A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

  Not yet reported Sanofi 23 participants Est. completion 2020-01-27 11 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02941367

  Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

  Not yet reported Sanofi 184 participants Est. completion 2017-08-04 16 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03130426

  Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

  Not yet reported Population Health Research Institute 161 participants Est. completion 2020-09-30 8 sites
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT03434119

  Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

  Not yet reported Sanofi 241 participants Est. completion 2019-01-07 85 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03439943

  Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

  Not yet reported University Hospital, Toulouse 156 participants Est. completion 2021-04-15 20 sites Stand-alone
  Other conditions: Parkinson Disease
  View official trial listing →
• Completed NCT NCT03492580

  A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

  Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
  Type 2 diabetesCardiovascular disease
  View official trial listing →
• Completed NCT NCT03529123

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

  Not yet reported Sanofi 247 participants Est. completion 2019-11-25 13 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03767543

  Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

  Not yet reported Sanofi 265 participants Est. completion 2020-10-23 32 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03798054

  Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

  Not yet reported Sanofi 878 participants Est. completion 2021-03-01 79 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03798080

  Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

  Not yet reported Sanofi 426 participants Est. completion 2020-12-01 45 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03819790

  The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

  Not yet reported LMC Diabetes & Endocrinology Ltd. 119 participants Est. completion 2019-11-19 3 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT03881995

  Effects of Insulin Glargine and Lixisenatide on the Brain

  Not yet reported University Hospital Tuebingen 1 participants Est. completion 2020-06-29 1 site
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT03959865

  GLP-1 REceptor Agonists and Real World EvIdeNce

  University of Padova 6000 participants Est. completion 2019-05-31 6 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04184947

  Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

  University of Padova 10000 participants Est. completion 2020-02-29 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04196231

  Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

  Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05114590

  Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

  Not yet reported Sanofi 124 participants Est. completion 2023-04-14 18 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05136287

  SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

  Jose Seijas Amigo 140 participants Est. completion 2024-01-01 11 sites
  Type 2 diabetes Other conditions: Weight Loss, Quality of Life, Safety Issues
  View official trial listing →
• Active, not recruiting NCT NCT05220917

  Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

  Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
  Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
  View official trial listing →
• Completed NCT NCT05413369

  iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

  Not yet reported Sanofi 582 participants Est. completion 2023-10-20 60 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT05804513

  The Effect of Lixisenatide on the Effect of Pituitary Hormones

  Not yet reported University of Tartu 10 participants Est. completion 2023-12-31 1 site
  Other conditions: Healthy, Type 1 Diabetes
  View official trial listing →
• Status unknown NCT NCT06449235

  Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

  Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
  Other conditions: Type2diabetes
  View official trial listing →
• Completed NCT NCT06716424

  A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

  Not yet reported Sanofi 105 participants Est. completion 2026-06-12 10 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Enrolling by invitation NCT NCT07117240

  Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

  Not yet reported Medical University of Warsaw 100 participants Est. completion 2028-07-10 1 site Stand-alone
  Other conditions: Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
  View official trial listing →
• Not yet recruiting NCT NCT07173712

  Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

  Not yet reported Yanbing Li 324 participants Est. completion 2027-12-31
  Type 2 diabetes
  View official trial listing →
• Active, not recruiting NCT NCT07188545

  Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

  Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
  Metabolic syndrome
  View official trial listing →

Not yet reported.

Not yet reported.

• ClinicalTrials.gov — NCT01517412

Also known as: Lixisenatide, Lixisenatide (AVE0010)

No related coverage yet.